Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 274-040-4 | CAS number: 69563-51-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- yes
- Remarks:
- Due to a Study Director oversight, the Study Plan was not sent to QA for review prior to performance of the study, in error. This deviation was considered not to affect the purpose or integrity of the study.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- yes
- Remarks:
- Due to a Study Director oversight, the Study Plan was not sent to QA for review prior to performance of the study, in error. This deviation was considered not to affect the purpose or integrity of the study.
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- N-(4-amino-9,10-dihydro-3-methoxy-9,10-dioxo-1-anthryl)benzenesulphonamide
- EC Number:
- 274-040-4
- EC Name:
- N-(4-amino-9,10-dihydro-3-methoxy-9,10-dioxo-1-anthryl)benzenesulphonamide
- Cas Number:
- 69563-51-5
- Molecular formula:
- C21H16N2O5S
- IUPAC Name:
- N-(4-amino-3-methoxy-9,10-dioxo-9,10-dihydroanthracen-1-yl)benzenesulfonamide
- Test material form:
- other: Solid
- Details on test material:
- None
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 12-45
- Expiration date of the lot/batch: 05 March 2019
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature in the dark
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories B.V., Horst, The Netherlands
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 to 12 weeks
- Weight at study initiation: 15 to 23 g
- Housing: suspended solid floor polypropylene cages furnished with softwood woodflakes
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25
- Humidity (%): 30 to 70
- Air changes (per hr): 15/hr
- Photoperiod (hrs dark / hrs light): 12 hrs light
Study design: in vivo (LLNA)
- Vehicle:
- propylene glycol
- Concentration:
- 25 %, 10 % and 5 % W/W
- No. of animals per dose:
- Four female mice
- Details on study design:
- Test Item Formulation and Experimental Preparation
For the purpose of the study, the test item was freshly prepared as a suspension in propylene glycol. This vehicle was chosen as it produced the highest concentration that was suitable for dosing. The concentrations used are given in the procedure section. The test item was formulated within 2 hours of being applied to the test system. It is assumed that the formulation was stable for this duration. No analysis was conducted to determine the homogeneity, concentration or stability of the test item formulation. This is an exception with regard to GLP and has been reflected in the GLP compliance statement.
Procedure
Preliminary Screening Test
Using available information regarding the systemic toxicity/irritancy potential of the test item, a preliminary screening test was performed using one mouse. The mouse was treated by daily application of 25 µL of the test item at a maximum attainable concentration of 25 % w/w in propylene glycol, to the dorsal surface of each ear for three consecutive days (Days 1, 2, 3). The mouse was observed twice daily on Days 1, 2 and 3 and once daily on Days 4, 5 and 6. Local skin irritation was scored daily. Any clinical signs of toxicity, if present, were also recorded. The body weight was recorded on Day 1 (prior to dosing) and on Day 6. The thickness of each ear was measured using a Mitutoyo 547 300S gauge (Mitutoyo Corporation), pre dose on Day 1, post dose on Day 3 and on Day 6. Any changes in the ear thickness were noted. Mean ear thickness changes were calculated between time periods Days 1 and 3 and Days 1 and 6. A mean ear thickness increase of equal to or greater than 25% was considered to indicate excessive irritation and limited biological relevance to the endpoint of sensitization.
Main Test
Test Item Administration
Groups of four mice were treated with the test item at concentrations of 25%, 10% or 5% w/w in propylene glycol. The preliminary screening test suggested that the test item would not produce systemic toxicity or excessive local skin irritation at the highest suitable concentration. The mice were treated by daily application of 25 µL of the appropriate concentration of the test item to the dorsal surface of each ear for three consecutive days (Days 1, 2, 3). The test item formulation was administered using an automatic micropipette and spread over the dorsal surface of the ear using the tip of the pipette. A further group of four mice received the vehicle alone in the same manner.
3H-Methyl Thymidine Administration
Five days following the first topical application of the test item or vehicle (Day 6) all mice were injected via the tail vein with 250 µL of phosphate buffered saline (PBS) containing 3H methyl thymidine (3HTdR: 80 µCi/mL, specific activity 2.0 Ci/mmoL, ARC UK Ltd) giving a total of 20 µCi to each mouse.
Observations
Clinical Observations: All animals were observed twice daily on Days 1, 2 and 3 and on a daily basis on Days 4, 5 and 6. Any signs of toxicity or signs of ill health during the test were recorded.
Body Weights: The body weight of each mouse was recorded on Day 1 (prior to dosing) and Day 6 (prior to termination).
Terminal Procedures
Termination:
Five hours following the administration of 3HTdR all mice were killed by carbon dioxide asphyxiation. The draining auricular lymph nodes from the four mice were excised and pooled for each experimental group. For each group 1 mL of PBS was added to the pooled lymph nodes.
Preparation of Single Cell Suspension:
A single cell suspension of pooled lymph node cells was prepared by gentle mechanical disaggregation through a 200 mesh stainless steel gauze. The lymph node cells were rinsed through the gauze with 4 mL of PBS into a petri dish labeled with the study number and dose concentration. The lymph node cell suspension was transferred to a centrifuge tube. The petri dish was washed with an additional 5 mL of PBS to remove all remaining lymph node cells and these were added to the centrifuge tube. The pooled lymph node cells were pelleted at 1400 rpm (approximately 190 g) for 10 minutes. The pellet was re suspended in 10 mL of PBS and re pelleted. To precipitate out the radioactive material, the pellet was re suspended in 3 mL of 5 % Trichloroacetic acid (TCA).
Determination of 3HTdR Incorporation:
After approximately 18 hours incubation at approximately 4 °C, the precipitates were recovered by centrifugation at 2100 rpm (approximately 450 g) for 10 minutes, re suspended in 1 mL of TCA and transferred to 10 mL of scintillation fluid (Optiphase 'Trisafe'). 3HTdR incorporation was measured by β scintillation counting. The "Poly Q™" vials containing the samples and scintillation fluid were placed in the sample changer of the scintillator and left to stand in darkness for approximately 20 minutes. The purpose of this period of time in darkness was to reduce the risk of luminescence, which has been shown to affect the reliability of the results. After approximately 20 minutes, the vials were shaken vigorously. The number of radioactive disintegrations per minute was then measured using the Beckman LS6500 scintillation system (Beckman Instruments Inc, Fullerton, CA, USA). - Positive control substance(s):
- other: Phenylacetaldehyde (>90%)
- Statistics:
- No data
Results and discussion
- Positive control results:
- The Stimulation Index expressed as the mean radioactive incorporation for the treatment group divided by the mean radioactive incorporation of the vehicle control group is as follows:
At 5 % (v/v) concentration in propylene glycol the stimulation index was 14.82 (positive).
Conclusion
Phenyl acetaldehyde (>90%) was considered to be a sensitizer under the conditions of the test.
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Value:
- 2.6
- Test group / Remarks:
- 5%
- Remarks on result:
- other: Variability not specified
- Parameter:
- SI
- Value:
- 1.96
- Test group / Remarks:
- 10%
- Remarks on result:
- other: Variability not specified
- Parameter:
- SI
- Value:
- 4.37
- Test group / Remarks:
- 25%
- Remarks on result:
- other: Variability not specified
Any other information on results incl. tables
Preliminary Screening Test
Red colored staining of the ears and fur was noted post dose on Day 1 and at all subsequent observations. Red colored staining of the ears prevented accurate evaluation of erythema on Days 2 and 3. No visual local skin irritation was noted on Day 1 and Days 4 to 6. No signs of systemic toxicity or irritation indicated by an equal to or greater than 25% increase in mean ear thickness were noted. Based on this information the dose levels selected for the main test were 25%,10% and 5% w/w in propylene glycol.
Main Test
Clinical Observations and Mortality Data
Red colored staining of the ears and fur was noted in all test animals. There were no deaths. No signs of systemic toxicity were noted in the test or control animals during the test.
Body Weight
Body weight change of the test animals between Day 1 and Day 6 was comparable to that observed in the corresponding control group animals over the same period.
Clinical Observations, Body Weight and Mortality Data – Preliminary Screening Test
Concentration |
Animal Number |
Body Weight (g) |
Day |
|||||||||
1 |
2 |
3 |
4 |
5 |
6 |
|||||||
Day 1 |
Day 6 |
Pre-Dose |
Post Dose |
Pre-Dose |
Post Dose |
Pre-Dose |
Post Dose |
|||||
25 |
S-1 |
16.6 |
16.7 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 = No signs of systemic toxicity
Fs = Red colored staining of the ears and fur
Local Skin Irritation – Preliminary Screening Test
Concentration |
Animal Number |
Local Skin Irritation |
|||||||||||
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
||||||||
left |
right |
left |
right |
left |
right |
left |
right |
left |
right |
left |
right |
||
25 |
S-1 |
0 |
0 |
Rs |
Rs |
Rs |
Rs |
0 |
0 |
0 |
0 |
0 |
0 |
Rs = Red colored staining of the ears prevented accurate evaluation of erythema
Measurement of Ear Thickness and Mean Ear Thickness Changes – Preliminary Screening Test
Concentration |
Animal Number |
Ear Thickness Measurement (mm) |
|||||
Day 1 |
Day 3 |
Day 6 |
|||||
pre‑dose |
post dose |
||||||
left |
right |
left |
right |
left |
right |
||
25 |
S-1 |
0.19 |
0.21 |
0.22 |
0.23 |
0.21 |
0.22 |
overall mean (mm) |
0.20 |
0.23 |
0.22 |
||||
overall mean ear thickness change (%) |
na |
12.50 |
7.50 |
na = Not applicable
Disintegrations per Minute, Disintegrations per Minute/Node and Stimulation Index
Concentration |
dpm |
dpm/Nodea |
Stimulation Indexb |
Result |
Vehicle |
4111.34 |
513.92 |
na |
na |
5 |
10680.40 |
1335.05 |
2.60 |
Negative |
10 |
8068.34 |
1008.54 |
1.96 |
Negative |
25 |
17973.29 |
2246.66 |
4.37 |
Positive |
dpm=Disintegrations per minute
a = Disintegrations per minute/node obtained by dividing the disintegrations per minute value by 8 (total number of lymph nodes)
b = Stimulation Index of 3.0 or greater indicates a positive result
na = Not applicable
Individual Clinical Observations and Mortality Data
Concentration |
Animal Number |
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
|||
Pre-Dose |
Post Dose |
Pre-Dose |
Post Dose |
Pre-Dose |
Post Dose |
|||||
Vehicle |
1-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5 |
2-1 |
0 |
0Fs |
0 |
0Fs |
0 |
0Fs |
0 |
0 |
0 |
2-2 |
0 |
0Fs |
0 |
0Fs |
0 |
0Fs |
0 |
0 |
0 |
|
2-3 |
0 |
0Fs |
0 |
0Fs |
0 |
0Fs |
0 |
0 |
0 |
|
2-4 |
0 |
0Fs |
0 |
0Fs |
0 |
0Fs |
0 |
0 |
0 |
|
10 |
3-1 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
0 |
3-2 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
0 |
|
3-3 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
0 |
|
3-4 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
0 |
|
25 |
4-1 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
4-2 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
|
4-3 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
|
4-4 |
0 |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0Fs |
0 |
0 |
0= No signs of systemic toxicity
Fs = Red colored staining of the ears and fur
Individual Body Weights and Body Weight Change
Concentration |
Animal Number |
Body Weight (g) |
Body Weight Change (g) |
|
Day 1 |
Day 6 |
|||
Vehicle |
1-1 |
21.1 |
20.2 |
-0.9 |
1-2 |
17.1 |
17.5 |
0.4 |
|
1-3 |
20.1 |
21.5 |
1.4 |
|
1-4 |
20.6 |
21.6 |
1.0 |
|
5 |
2-1 |
18.0 |
19.1 |
1.1 |
2-2 |
20.0 |
20.2 |
0.2 |
|
2-3 |
19.7 |
20.3 |
0.6 |
|
2-4 |
21.2 |
21.4 |
0.2 |
|
10 |
3-1 |
18.3 |
17.9 |
-0.4 |
3-2 |
20.3 |
21.1 |
0.8 |
|
3-3 |
21.2 |
21.6 |
0.4 |
|
3-4 |
17.8 |
18.0 |
0.2 |
|
25 |
4-1 |
18.6 |
19.8 |
1.2 |
4-2 |
18.1 |
17.7 |
-0.4 |
|
4-3 |
16.5 |
17.3 |
0.8 |
|
4-4 |
17.7 |
17.7 |
0.0 |
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Conclusions:
- FAT 36034/H was considered to be a sensitizer at concentration of 25% under the conditions of the test. However, the test item did not showed stimulation index of > 3 at concentration of 10%. The substance is not a sensitiser at concentration of 10% in LLNA assay.
- Executive summary:
A study was performed as per OECD 429 guideline to assess the skin sensitization potential of FAT 36034/H in the CBA/Ca strain mouse following topical application to the dorsal surface of the ear. Following a preliminary screening test in which no clinical signs of toxicity were noted at a maximum attainable concentration of 25 % w/w, this concentration was selected as the highest dose investigated in the main test of the Local Lymph Node Assay. Three groups, each of four animals, were treated with 50 µL (25 µL per ear) of the test item as a suspension in propylene glycol at concentrations of 25 %, 10 % or 5 % w/w. A further group of four animals was treated with propylene glycol alone.
The Stimulation Index expressed as the mean radioactive incorporation for each treatment group divided by the mean radioactive incorporation of the vehicle control group are as follows:
At 5 % (w/w) concentration in propylene glycol the stimulation index was 2.60 (negative)
At 10 % (w/w) concentration in propylene glycol the stimulation index was 1.96 (negative)
At 25 % (w/w) concentration in propylene glycol the stimulation index was 4.37 (positive)
The test item was considered to be a sensitizer at concentration of 25 % under the conditions of the test. However, the test item did not showed stimulation index of > 3 at concentration of 10 %. The substance is not a sensitiser at concentration of 10 % in LLNA assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.